Biogen (BIIB) PT Lowered to $244 at Barclays
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $213.31 +1.99%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 13 | New: 26
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 13 | New: 26
Join SI Premium – FREE
Barclays analyst Carter Gould lowered the price target on Biogen (NASDAQ: BIIB) to $244.00 (from $280.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- SmartFinancial (SMBK) PT Raised to $60 at Benchmark on Higher Valuation
- Clean Energy Fuels (CLNE) PT Lowered to $2.50 at Raymond James
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
